Inquiry Basket
Loading ......
Vitamin D is widely recognized for its role in calcium homeostasis and bone health, but its biological influence extends well beyond the skeletal system. The immune system is an important site of vitamin D activity, particularly within activated T cells, B cells, monocytes, macrophages, and dendritic cells (DCs). A key point, however, is that 25-hydroxyvitamin D [25(OH)D] is primarily a circulating precursor and biomarker of vitamin D status rather than the principal active immune-regulatory molecule.
For immune regulation, 25(OH)D can be locally converted into the biologically active metabolite 1,25-dihydroxyvitamin D [1,25(OH)2D] through the action of CYP27B1. The resulting 1,25(OH)2D binds to the vitamin D receptor (VDR), which is expressed at higher levels in activated immune cells. This local vitamin D metabolic system allows immune cells to respond to the availability of 25(OH)D while controlling the strength and direction of immune responses. The overall effect is not simply to "boost" or "suppress" immunity. Instead, vitamin D signaling helps shape adaptive immune activity, generally favoring a more regulated response by limiting excessive inflammatory T-cell activity while restraining B-cell proliferation, differentiation, and antibody production.
The immune effects associated with 25(OH)D depend largely on its conversion to 1,25(OH)2D. This conversion is particularly relevant in immune cells and their surrounding microenvironment, where CYP27B1 can provide a local source of active vitamin D. This mechanism helps explain why measuring circulating 25(OH)D and understanding cellular vitamin D metabolism are related but distinct concepts. A blood 25(OH)D measurement primarily reflects systemic vitamin D status, whereas the immunological response depends on factors including cellular CYP27B1 activity, VDR expression, availability of substrate, and interactions among immune cells.
Dendritic cells can act as an important metabolic and immunological bridge. When DCs undergo maturation, for example following inflammatory stimulation or interaction with T cells, CYP27B1 expression can increase. These cells can then convert 25(OH)D into 1,25(OH)2D and influence nearby T cells through local signaling. Vitamin D-binding protein (DBP) may also affect this process by influencing how much circulating 25(OH)D is available to cells. Activated T cells themselves show increased VDR expression, with optimal VDR expression occurring after activation rather than immediately after resting cells encounter a stimulus. T cells may also express vitamin D metabolic machinery, supporting the possibility of local or intracellular production of active vitamin D. These observations provide a mechanistic basis for several routes through which 25(OH)D may influence T-cell responses.
T cells are particularly responsive to vitamin D after activation. Once VDR expression increases, 1,25(OH)2D can bind VDR and influence transcriptional programs associated with proliferation, differentiation, cytokine production, and immune regulation. The relationship can occur through several interconnected pathways. Systemically available 1,25(OH)2D may act directly on T cells. Alternatively, monocytes, macrophages, or DCs can locally convert 25(OH)D into active vitamin D and influence T cells through antigen presentation and paracrine signaling. Activated T cells may also contribute to their own local vitamin D response by converting 25(OH)D into 1,25(OH)2D. This means that the immune effects attributed to 25(OH)D should not be viewed as a simple direct action of the circulating metabolite on every immune cell. Instead, they emerge from a local vitamin D metabolic network involving precursor availability, CYP27B1, VDR, and communication between immune cells.
One of the most consistent immunological themes associated with active vitamin D is its ability to restrain inflammatory T-cell responses. 1,25(OH)2D can reduce T-cell proliferation and suppress production of inflammatory cytokines such as interferon-γ (IFN-γ) and interleukin-17 (IL-17). These effects are particularly relevant to Th1- and Th17-associated immune responses. In addition, vitamin D signaling in monocytes and other antigen-presenting cells can reduce production of IL-12 and IL-23, cytokines that support Th1 and Th17 differentiation and maintenance. CD8+ T cells can also respond to active vitamin D signaling. Experimental observations indicate reductions in proliferation and inflammatory cytokine expression, including IFN-γ and tumor necrosis factor-α (TNF-α). Importantly, immune regulation does not necessarily mean complete loss of immune competence; vitamin D can modify cytokine profiles without uniformly eliminating cytotoxic activity.
Vitamin D signaling can also shift T-cell responses toward a more regulatory phenotype. 1,25(OH)2D has been associated with increased development or expansion of FOXP3-positive regulatory T cells (Tregs) and CD4+CD25+ regulatory populations. At the cytokine level, vitamin D can favor regulatory mediators such as IL-10 and may increase signals associated with Th2 or regulatory responses, including IL-4, IL-5, and TGF-β in particular experimental settings. This balance is important because a healthy immune system needs both effective defense and appropriate restraint. Excessive Th1 or Th17 activity can contribute to persistent inflammation and loss of immune tolerance. By reducing inflammatory cytokine production while supporting regulatory pathways, vitamin D signaling may help maintain a less inflammatory immune environment.
Vitamin D also affects how immune cells respond to their tissue environment. Active vitamin D can stimulate T-cell expression of CCR10, a chemokine receptor involved in immune-cell trafficking and tissue localization. This adds another layer to vitamin D-mediated immune regulation: the pathway can influence not only what T cells produce, but also how they respond to chemotactic signals and where they participate in immune responses.
Like activated T cells, B cells can increase VDR expression following activation. This makes B cells potential direct targets of 1,25(OH)2D. The effects are generally characterized by reduced B-cell proliferation and differentiation. Active vitamin D can also influence B-cell survival, antibody production, and the ability of B cells to participate in T-cell activation. These effects can occur directly through VDR signaling within B cells or indirectly through changes in antigen-presenting cells and T-cell helper responses.
One important mechanism involves regulation of the cell cycle. 1,25(OH)2D can increase expression of p27, a cell-cycle regulatory protein, contributing to suppression of B-cell proliferation. At the same time, active vitamin D can promote apoptosis in susceptible B-cell populations. Together, these effects can reduce the expansion of activated B cells and limit the magnitude of downstream humoral immune responses. This does not mean that vitamin D simply eliminates B cells. Rather, its signaling can impose regulatory constraints on activated B-cell expansion, particularly under conditions where strong immune activation is occurring.
B-cell activation normally leads to differentiation into antibody-producing plasma cells and the generation of memory B cells. Active vitamin D can interfere with these differentiation pathways. Exposure to 1,25(OH)2D has been associated with reduced plasma-cell differentiation and decreased production of immunoglobulins such as IgM and IgG. The generation of class-switched memory B cells can also be reduced. Through these mechanisms, vitamin D signaling can restrain the transition from B-cell activation to sustained antibody-producing responses. This is one reason vitamin D is considered an important regulator of excessive adaptive immune activation rather than simply an immune stimulant.
B cells can function not only as antibody-producing cells but also as antigen-presenting cells. Their ability to activate T cells depends partly on costimulatory molecules such as CD86. 1,25(OH)2D can reduce CD86 expression on B cells, potentially weakening their capacity to provide effective costimulatory signals to T cells. This creates another route through which vitamin D can influence adaptive immunity: by changing the interaction between antigen-presenting B cells and T cells.
The effects of vitamin D on T and B cells should not be considered independently. Adaptive immunity depends on extensive communication among T cells, B cells, dendritic cells, and other immune populations. For example, suppression of Th1- and Th17-associated signaling can indirectly influence B-cell activation and differentiation. Conversely, changes in B-cell antigen presentation and costimulatory activity can alter T-cell responses. This interconnected biology helps explain why some effects of 1,25(OH)2D on B cells may be mediated indirectly through antigen-presenting cells or T-cell helper signals. The final immune phenotype therefore reflects a combination of direct VDR signaling and changes in the cellular environment.
A useful way to understand vitamin D immunobiology is to consider it as a regulatory system rather than an immune "on/off switch." When immune cells become activated, increased VDR expression and local vitamin D metabolism can make them more responsive to 1,25(OH)2D. The resulting signaling tends to reduce excessive inflammatory T-cell proliferation and cytokine production, while promoting regulatory T-cell characteristics. At the B-cell level, it can limit proliferation, plasma-cell differentiation, memory-cell formation, and immunoglobulin production.
Vitamin D signaling can also influence antigen-presenting cells. Active vitamin D may promote a more tolerogenic dendritic-cell phenotype and alter cytokine production in ways that reduce the conditions favoring excessive Th1 and Th17 responses. This coordinated regulation is particularly relevant to the concept of immune tolerance. Rather than broadly suppressing immunity, vitamin D signaling may help prevent adaptive immune responses from becoming unnecessarily prolonged or inflammatory.
Because 25(OH)D is the major circulating form of vitamin D, it is widely used to assess vitamin D status. However, interpreting a 25(OH)D result in the context of immune function requires care. A circulating 25(OH)D concentration does not directly measure intracellular 1,25(OH)2D production or VDR activity in a particular immune-cell population. Local CYP27B1 expression, DBP availability, cellular activation state, VDR abundance, and inflammatory signals can all influence how immune cells respond to vitamin D. Consequently, 25(OH)D testing provides an important measure of vitamin D availability, but it should not be interpreted as a standalone measurement of immune function. In research settings, combining vitamin D status with cellular markers, cytokine profiles, VDR expression, CYP27B1 activity, or immune-cell phenotyping can provide a more complete picture of vitamin D-mediated immune regulation.
The ability of immune cells to locally activate vitamin D provides a biologically plausible connection between nutritional vitamin D status and adaptive immune regulation. The pathway links circulating 25(OH)D with cellular CYP27B1, active 1,25(OH)2D, VDR signaling, cytokine networks, and immune-cell differentiation. In T cells, the dominant pattern is the restriction of excessive Th1/Th17 activity together with support for regulatory pathways such as Treg and IL-10 signaling. In B cells, active vitamin D generally limits proliferation, plasma-cell differentiation, memory B-cell formation, and immunoglobulin production. These effects can be reinforced through changes in dendritic cells and T-cell help.
Importantly, these mechanisms do not establish that vitamin D supplementation or a particular 25(OH)D concentration will prevent or treat a specific immune-mediated disease. Clinical outcomes depend on disease biology, baseline vitamin D status, genetics, treatment context, and many other factors. The strongest interpretation is that vitamin D is an important immunoregulatory component of the cellular environment, with effects that are highly dependent on context.
25(OH)D regulates T-cell and B-cell function primarily through its local conversion to active 1,25(OH)2D, followed by VDR-mediated signaling. Activated T cells and B cells increase VDR expression, making them particularly responsive to this pathway. In T cells, active vitamin D can suppress proliferation and inflammatory Th1/Th17-associated cytokines such as IFN-γ and IL-17 while supporting regulatory pathways involving Tregs, IL-10, and other regulatory mediators. In B cells, it can restrict proliferation, promote apoptosis in activated populations, reduce plasma-cell and memory B-cell differentiation, and decrease immunoglobulin production. Dendritic cells, monocytes, and other antigen-presenting cells further amplify or shape these effects through local vitamin D metabolism.
The central concept is therefore not that 25(OH)D directly "turns down" immunity. Instead, 25(OH)D provides the substrate for a tightly regulated local vitamin D signaling system that helps coordinate inflammatory responses, immune tolerance, and communication between T cells and B cells. Understanding this distinction is essential when interpreting 25(OH)D measurements in immune research and when studying the relationship between vitamin D status and adaptive immunity.
25-OH vitamin D [25(OH)D] acts mainly as a precursor for the active metabolite 1,25(OH)2D. After local conversion by CYP27B1, 1,25(OH)2D binds to VDR in activated T cells and can reduce excessive T-cell proliferation and inflammatory cytokines such as IFN-γ and IL-17 while supporting regulatory T-cell responses.
1,25(OH)2D generally suppresses activated B-cell proliferation and differentiation. It can reduce plasma-cell formation, memory B-cell generation, and immunoglobulin production, including IgM and IgG, while promoting apoptosis in certain activated B-cell populations.
Yes. Active vitamin D signaling has been associated with the development and expansion of regulatory T cells, including FOXP3+ Tregs. It may also promote regulatory cytokine signaling, such as IL-10, helping shift immune responses away from excessive inflammatory activity.
CYP27B1 converts circulating 25(OH)D into biologically active 1,25(OH)2D within specific cells and tissues. Dendritic cells, monocytes, macrophages, and activated lymphocytes can contribute to this local vitamin D activation, allowing immune responses to be regulated at the cellular level.
No. A 25(OH)D test primarily reflects circulating vitamin D status and substrate availability. It does not directly measure immune-cell VDR activity, local CYP27B1-mediated conversion, or the strength of T-cell and B-cell responses. Immune regulation depends on several additional cellular and molecular factors.
References
| Target | Cat. No. | Product Name | Host | Application | |
| 25-OH Vitamin D | DMABA-JX119 | Rabbit Anti-25 OH Vitamin D monoclonal antibody, clone S594L4 | Rabbit | ELISA, LFIA, CLIA | Inquiry |
| DMABA-JX120 | Rabbit Anti-25 OH Vitamin D monoclonal antibody, clone S595K5 | Rabbit | ELISA, LFIA, CLIA | Inquiry | |
| DMAB-JXL2399 | Goat Anti-25-OH VD2/VD3 Monoclonal Antibody, clone 5C3 | CHO | ELISA, CLIA, LFIA | Inquiry | |
| DMAB2913 | Mouse Anti-25 OH Vitamin D3 monoclonal antibody, clone L35235N | Mouse | ELISA | Inquiry | |
| DMAB2914 | Mouse Anti-25 OH Vitamin D3 Monoclonal antibody, clone C2531M | Mouse | ELISA | Inquiry | |
| CABT-L1343W | Humanized Anti-Human 25-OH-VD Monoclonal antibody, clone 214I2T | Humanized | LFIA, CLIA | Inquiry | |
| CABT-L1344W | Humanized Anti-Human 25-OH-VD Monoclonal antibody, clone 214I5 | Humanized | PETIA | Inquiry |
| Target | Cat. No. | Product Name | Conjugate | Application | |
| 25-OH Vitamin D | DAG-WT2678 | 25-hydroxyvitamin D control | Unconjugated | Calibration, Control | Inquiry |
| DAG-WT2679 | 25-hydroxyvitamin D2 control | Unconjugated | Calibration, Control | Inquiry | |
| DAG-WT2680 | 25-hydroxyvitamin D3 control | Unconjugated | Calibration, Control | Inquiry | |
| DAG03219 | 25-OH Vitamin D3 [BSA] | BSA | ELISA, LFIA | Inquiry | |
| DAGA-126H | 25-OH Vitamin D [HRP] | HRP | ELISA | Inquiry | |
| DAGA-126K | 25-OH Vitamin D [KLH] | KLH | Immunogen | Inquiry | |
| DAG-WT6032B | 25-OH Vitamin D2 [BSA] | BSA | ELISA, LFIA | Inquiry |
| Target | Cat. No. | Product Name | Species Reactivity | Application | Detection Sample | |
| 25-OH Vitamin D | DEIA4458 | 25-OH Vitamin D ELISA Kit | Human | Quantitative | Serum, Plasma | Inquiry |
| DEIA1733 | 25 (OH) Vitamin D ELISA Kit | Human | Quantitative | plasma, serum | Inquiry | |
| DEIA002J | 25-OH Vitamin D direct (1-point calibration) ELISA Kit | Human | Quantitative | serum | Inquiry | |
| DEIA003J | 25-OH Vitamin D direct day ELISA Kit | Human | Quantitative | serum, fresh plasma | Inquiry | |
| DEIA004J | 25-OH Vitamin D direct ELISA Kit | Human | Quantitative | serum, fresh plasma | Inquiry | |
| DEIA005J | 25-OH Vitamin D Xpress ELISA Kit | Human | Quantitative | serum, fresh EDTA plasma | Inquiry | |
| DEIA006J | 25-OH Vitamin D ELISA Kit | Human | Quantitative | serum, plasma | Inquiry | |
| DEIA2219 | 25-OH Vitamin D (total) ELISA Kit 0 2 | Human | Quantitative | Serum | Inquiry | |
| DEIA-BJ574-1 | Human 25 (OH) D3 ELISA kit | Human | Quantitative | Serum, plasma and other biological fluids. | Inquiry | |
| DEIA-BJ2145 | Rat 25 Hydroxy Vitamin D3 ELISA Kit | Rat | Quantitative | Serum, plasma, cell culture supernatants, body fluid and tissue homogenate | Inquiry | |
| DEIA-NS2651 | 25OH-D (Total 25-OH Vitamin D) ELISA Kit | Universal | Quantitative | Serum, plasma, cellculture supernatant and other biological samples. | Inquiry | |
| DEIA-BJ648 | Human 25 Hydroxy Vitamin D ELISA kit | Human | Quantitative | biological fluids. | Inquiry |
Loading ......
